** Shares of Australia's Alterity Therapeutics ATH.AX fall as much as 8.3% to A$0.011, on track for a third consecutive session of decline
** Stock hits its lowest level since Jan. 31
** Biotechnology co raises A$40.0 mln ($25.02 mln) in a placement at an issue price of A$0.011 per share
** Issue price represents a discount of 8.3% to stock's last close
** Co says funds will be used primarily to advance development of ATH434, a small molecule drug candidate for Parkinsonian disorders
** Stock up 43.8% this year, as of 0159 GMT
($1 = 1.5990 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。